The IMpower-132 trial for non small cell lung cancer
The IMpower-132 trial for non small cell lung cancer
Keynote lecture: Mutation signatures and targeting the DNA damage response
COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma
Current clinical landscape for ALK non-small cell lung cancer patients
Latest advances in treatment for ALK positive NSCLC
Highlights in early non-metastatic NSCLC and thoracic tumours
Combination strategies of immunotherapy in breast cancer
ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC
Safety analysis of entrectinib for NTRK fusion tumours
ASCEND-8: safety data of ceritinib with or without food in NSCLC
CheckMate142: Checkpoint combination therapy in first-line colorectal cancer
SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer